News for LegoChem Biosciences, Inc. (141080.KQ)

Seoul, South Korea, and Berlin, Germany October 16, 2023 – LegoChem Biosciences Inc. (LCB) and Glycotope GmbH (Glycotope) have entered into an exclusive...

By Chris Wack LegoChem Biosciences Inc. said Friday that it has entered into a research collaboration and license agreement with Amgen Inc. Under the deal, Amgen was granted rights to... | December 23, 2022

BELTSVILLE, Md. and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ:...

/PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and...

LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate July 12, 2022...

RemeGen, a Yantai biotech with a deep portfolio of antibody and dual therapies, completed a $410 million IPO on the Shanghai Star Exchange. Read more about other updates here.

/PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization...

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

SUZHOU, China, Jan. 2, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research,